Related Experiment Video
Updated: Oct 11, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
[Combinationpills for cardiovascular disease: the missing piece of evidence?]
Michiel L Bots1,2, Frans H Rutten1, Jan Westerik3
1Universitair Medisch Centrum Utrecht, Universiteit Utrecht, Julius Centrum voor Gezondheidswetenschappen en Eerstelijnsgezondheidszorg.
Abstract:
In the literature the terms fixed dose combination (FDC) or single pill combination (SPC) emerged as synonyms for the combinationpill. Studies consistently indicated that a cardiovascular FDC increases medication adherence and improves blood and lipid levels. TIPS-3 recently added evidence by showing that a cardiovascular FDC reduces events compared to non-pharmacological treatment. Do we now have all the evidence for widespread implementation of FDC? Some feel the need for direct comparisons between FDC and the use of separate pills with the same FDC components. That will probably never happen. So the best way forward is that, when indicated, physicians put patients on cardiovascular preventive medication, and when stable and adequately controlled, discusses with the patient about the possibilities for an FDC. This will not be applicable to all patients, but likely a large percentage. Please note 94% of vascular patients very much prefers an FDC above separate individual pills.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

